Pinnacle Wealth Management Advisory Group LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,720 shares of the company’s stock after selling 50 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC’s holdings in Eli Lilly and were worth $395,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Ethic Inc. grew its holdings in shares of Eli Lilly and by 15.0% during the first quarter. Ethic Inc. now owns 13,230 shares of the company’s stock worth $2,472,000 after buying an additional 1,728 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in shares of Eli Lilly and by 11.0% during the first quarter. Perigon Wealth Management LLC now owns 8,242 shares of the company’s stock worth $1,540,000 after buying an additional 816 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG boosted its position in shares of Eli Lilly and by 10.1% in the first quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 101,540 shares of the company’s stock worth $18,969,000 after acquiring an additional 9,333 shares during the last quarter. Payden & Rygel boosted its position in shares of Eli Lilly and by 1,134.3% in the second quarter. Payden & Rygel now owns 117,225 shares of the company’s stock worth $26,905,000 after acquiring an additional 107,728 shares during the last quarter. Finally, Usca Ria LLC boosted its position in shares of Eli Lilly and by 2.9% in the second quarter. Usca Ria LLC now owns 17,217 shares of the company’s stock worth $3,952,000 after acquiring an additional 483 shares during the last quarter. Institutional investors and hedge funds own 81.65% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 202,102 shares of the firm’s stock in a transaction dated Friday, July 2nd. The stock was sold at an average price of $232.94, for a total transaction of $47,077,639.88. Following the transaction, the insider now owns 109,251,475 shares in the company, valued at $25,449,038,586.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have sold 1,044,132 shares of company stock worth $257,735,592. Company insiders own 0.13% of the company’s stock.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Monday, August 2nd. The company reported $1.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.89 by ($0.02). The firm had revenue of $6.74 billion during the quarter, compared to the consensus estimate of $6.59 billion. Eli Lilly and had a net margin of 22.71% and a return on equity of 119.12%. Eli Lilly and’s revenue was up 22.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.89 EPS. On average, analysts anticipate that Eli Lilly and Company will post 7.87 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 10th. Shareholders of record on Friday, August 13th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 1.46%. The ex-dividend date was Thursday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is currently 42.88%.
Several equities research analysts recently issued reports on the stock. Morgan Stanley raised their target price on shares of Eli Lilly and from $207.00 to $275.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and from $270.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. Truist assumed coverage on shares of Eli Lilly and in a research note on Tuesday, July 27th. They issued a “buy” rating and a $262.00 price target for the company. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and from $252.00 to $270.00 and gave the company a “conviction-buy” rating in a research note on Monday, June 14th. Finally, Truist Securities boosted their target price on shares of Eli Lilly and from $225.00 to $262.00 and gave the company a “buy” rating in a research note on Friday, July 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $250.41.
Eli Lilly and Company Profile
Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.
Featured Story: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.